welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
Horizon Therapeutics plc today announced an integrated analysis of efficacy data from the Phase 2 and Phase 3 clinical trials of teprotumumab will be presented during an oral session at the American College of Rheumatology (ACR) Annual Meeting, Nov. 8-13 in Atlanta. The U.S. Food and Drug Administration is currently evaluating under Priority Review a Biologics License Application (BLA) for teprotumumab in the treatment of active thyroid eye disease (TED). If approved, teprotumumab would be the first FDA-approved medicine for active TED. The Prescription Drug User Fee Act (PDUFA) goal date is March 8, 2020. Teprotumumab is an investigational medicine and its safety and efficacy have not been established.
Oral Presentation: Teprotumumab, A Novel Biologic for Active Thyroid Eye Disease (abstract 1807)
Date: Monday, November 4, 2019
Time: 2:45-3:00 PM ET
The event has ended.
Immunotherapy for Graves’ OphthalmopathyPurpose of Review: In recent years, imm...
High Serum Cholesterol is a Novel Risk Factor for Graves’ Orbitopathy: Results of a Cross-Sectional StudyBackground: Limited data suggest that t...
Jimmy Uddin, MB Bchir, MA, FRCOphthJimmy Uddin is a Senior Consultant Ophth...
Eric Hink, MDEric Hink is Associate Professor of opht...
Gut Microbes May Play Role in Graves ’ Disease Diagnosis, Thyroid AutoimmunityThe abundance and diversity of intestina...
A Prospective, Randomized Trial of Intravenous Glucocorticoids Therapy With Different Protocols for Patients With Gr...Background: For patients with active mo...
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...